E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The trial compares single-agent rituximab as maintenance treatment versus observation after combined immunochematherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than 65 years with previously B-cell chronic lymphocytic leukemia. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10009310 |
E.1.2 | Term | CLL |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary: to demonstrate superiority in 3-year progression-free survival from randomization (PFS) of rituximab maintenance over observation in patients in CR or PR after induction by FCR |
|
E.2.2 | Secondary objectives of the trial |
Secondary: Determine overall response rate (CR and PR) after induction therapy, rates of phenotypic responses, duration of phenotypic, clinical responses, response rates and time-related parameters in biological subgroups, adverse events, CD4/CD8 counts, immunoglobulin levels, incidence of Coombs-positive haemolytic anemiae, pharmacokinetics of rituximab, prognostic impact of the FcRIII genotype, quality of life (QoL), pharmacoeconomics |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria • B-CLL • Matutes score : 4 or 5 • Binet stages B and C • Age > 65 years old • No previous treatment of CLL by chemotherapy, radiotherapy or immunotherapy, except glucocorticoids < 1 month • Patient’s written informed consent • Life expectancy > 6 months
Inclusion criteria at randomization
• Patients having received the full induction phase with 4 FC and 6 rituximab courses (with/without dose adjustments as per protocol) • Complete or partial response according to NCI criteria at the end of induction phase • Recovery from FCR toxicities • Patient willingness to continue on protocol |
|
E.4 | Principal exclusion criteria |
• ECOG PS 2 to 4 • Presence of 17 deletion by FISH • Clinically significany auto-immune cytopenia • History of another malignancy in CR less than 5 years, except basal cell skin cancer or tumor treated curatively by surgery • Any severe co-morbidities of heart, pulmonary function • CIRS > 6 • Known hypersensitivity to murine proteins or to any of the study drugs or their components • Transformation into an aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma, or prolymphocytic leukemia) • Active bacterial, viral or fungal infection • Seropositivity HIV, hepatitis C or hepatitis B (unless clearly due to vaccination) • Total bilirubin, alkaline phosphatases and aminotransferases > 2 x ULN • Creatinine clearance < 60 ml/min calculated according to the formula of Cockcroft and Gault • Any coexisting medical or psychological condition that would preclude participation to the required study procedures • Patient with mental deficiency preventing proper understanding of the requirements of treatment •
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The objective of this study is to demontrate a clinically relevant statistical superiority in 3-year progression free survival (PFS) from randomization of rituximab maintenance over observation in CR and PR after induction treatment by fludarabine, cyclophosphamide and rituximab. The PFS is defined as the time elapsed between randomization and proressive disease, relapse, death related to B-CLL or initiation of a new treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 79 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 10 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |